NYSE: MANE · Listed Feb 4, 2026
Veradermics IPO
IPO price
$17.00
Veradermics (MANE) priced its IPO at $17.00 a share and has traded on NYSE since Feb 4, 2026.
MANE today$125.99+641.12%since IPO15-min delayed · as of 6:13:12 AM EST on Nov 19, 2026
See the MANE quoteFirst trading day · Feb 4, 2026
- IPO price
- $17.00
- above the range of $14 to $16
- First trade
- $34.00
- +100.00% from the IPO price
- First-day last trade
- $37.77
- +122.18% from the IPO price, regular session
- Raise
- $256.32M
- before the underwriters' option
These numbers are from the first trading day, Feb 4, 2026.
How MANE did against the market
MANE against the market, from its first trade at 1:25 ET to the last trade of the session.
- MANE from its first trade
- +11.09%
- Against the market (QQQ)
- +10.6 pts
MANE rose 11.1% from its first trade to the last trade of the session. That is 10.6 points better than the market.
Same-day moves do not show that MANE caused them. The market is QQQ, the Nasdaq-100 ETF.
The debut race
MANE against other big listings, as the percent change from each stock's own IPO price.
The first 30 trading days. Each point is the last regular-session trade of a day.
The first trading day.
The first trading day.
The IPO scoreboard
MANE against 6 other big listings: the return from each IPO's own price at the first trade, the close of day 1, day 5, and day 30.
| IPO | Raised | First trade | Day 1 close | Day 1 close, as a bar | Day 5 | Day 30 |
|---|---|---|---|---|---|---|
| Veradermics '26 | $256.32M | +100.00% | +122.18% | +140.00% | +247.00% | |
| Figma '25 | $1.22B | +157.58% | +252.42% | +173.64% | +69.64% | |
| Circle '25 | $1.05B | +122.58% | +168.45% | +278.18% | +622.98% | |
| Reddit '24 | $748M | +38.24% | +47.97% | +69.90% | +40.32% | |
| Arm '23 | $5.23B | +10.00% | +23.76% | +3.63% | -3.06% | |
| Klarna '25 | $1.37B | +30.00% | +16.14% | +13.73% | -7.33% | |
| CoreWeave '25 | $1.5B | -2.50% | +0.02% | +34.32% | +28.42% |
Day 1 is the last regular-session trade of the first day. Day 5 and day 30 are the last trade of the fifth and thirtieth trading day, counting the listing day as day 1. A cell fills in when that day has traded.
The offering
The Veradermics IPO offers 15.08M shares to raise $256.32M, before any underwriters' option.
- Expected price range
- $14 to $16
- IPO price
- $17.00
- Shares offered
- 15.08M
- Money raised
- $256.32M
- Listing date
- Feb 4, 2026
- Exchange
- NYSE
- Security
- Ordinary Shares
Money raised, against the largest IPOs
- Alibaba '14$21.77B
- Facebook '12$18.41B
- Rivian '21$11.93B
- Uber '19$8.1B
- Arm '23$5.23B
- Veradermics$256.32M
Where MANE ranks
Veradermics's market cap against the largest US-listed companies.
Market cap, against the largest US-listed companies
- AAPL$5.12T
- MSFT$3.77T
- NVDA$3.65T
- GOOGL$3.47T
- AMZN$2.9T
- TSM$1.88T
- AVGO$1.69T
- META$1.58T
- TSLA$1.52T
- BRK.B$1.22T
- MANE$5.27B
Filings and the company
What Veradermics has disclosed to the SEC, and the basic facts about the listing.
8-K filings
Material events that Veradermics discloses to the SEC on Form 8-K.
- Quarterly earningsNov 10, 2026
On November 10, 2026, Veradermics, Incorporated issued a press release announcing its financial results for the quarter ended September 30, 2026.
- Clinical trial resultsNov 9, 2026
At Month 12 of treatment with VDPHL01, 89.1% of participants in the BID dose arm and 79.8% of participants in the QD dose arm reported visible improvement in hair coverage on the Androgenetic Alopecia Impact Rating Scale (AAIRS). Additionally, 68.0% of participants in the BID dose arm and 48.4% of participants in the QD dose arm achieved 'improved' or 'much improved' hair coverage on the AAIRS.
- Business updateOct 19, 2026
On October 19, 2026, Veradermics, Incorporated issued a press release announcing positive topline data from the Phase 3 clinical trial, Study '304' evaluating VDPHL01 in males with mild-to-moderate pattern hair loss.
- Investor presentationJul 15, 2026
A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and the presentation the Company presented on the conference call and webcast is furnished as Exhibit 99.2 to this Current Report on Form 8-K, and both are incorporated by reference herein.
- Public offeringMay 1, 2026
On May 1, 2026, Veradermics, Incorporated (the "Company") closed its underwritten public offering (the "Public Offering") of 3,843,790 shares of the Company's common stock, par value $0.00001 per share (the "Common Stock"), at a public offering price of $100.00 per share, pursuant to the Company's registration statements on Form S-1 (File Nos. 333-295356 and 333-295420). In addition, the Company has granted the underwriters an option for a period of 30 days to purchase up to an additional 576,568 shares of Common Stock at the public offering price, less underwriting discounts and commissions.
About Veradermics
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
- Ticker
- MANE
- Exchange
- NYSE
- Market
- stocks
- Type
- CS
- Currency
- USD
- Industry
- PHARMACEUTICAL PREPARATIONS
- Employees
- 21
- Listed
- Feb 4, 2026
- Security
- Ordinary Shares
Frequently asked questions
What was the Veradermics IPO price?
$17.00 a share.
When did Veradermics go public?
Veradermics listed on NYSE on Feb 4, 2026 under the ticker MANE.
How much did the Veradermics IPO raise?
$256.32M, before any underwriters' option.
How did Veradermics open on its first day?
MANE first traded at $34.00, +100.00% from the IPO price of $17.00.
How did MANE close on its first day?
Its last regular-session trade was $37.77, +122.18% from the IPO price of $17.00.
What was the MANE first-day trading range?
$32.00 to $40.01 in the regular session.
How many MANE shares traded on the first day?
3.14M shares in the regular session.
How many shares did Veradermics sell in its IPO?
15.08M shares.
How did MANE do against the market on its first day?
MANE rose 11.1% from its first trade to the last trade of the session. That is 10.6 points better than the market (QQQ, the Nasdaq-100 ETF).
What exchange is MANE listed on?
Veradermics lists on NYSE under the ticker MANE.
Build with Massive
Get the MANE data behind this page
| What the page shows | Endpoint |
|---|---|
| Offering terms and dates | /vX/reference/ipos |
| Price | /v3/snapshot |
| Chart, VWAP, and the market comparison | /v2/aggs/ticker/MANE/range/5/minute |
| Market cap | /v3/reference/tickers/MANE |
| News | /v2/reference/news |
| Filings | /vX/disclosures |
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.